Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 251

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 251
---
 and co-commercialize WVE-003. As a result of this decision, the collaboration with Wave has completed. The impact on the consolidated financial statements from the completion of the partnership was not material.

F-42

Other R& D Related Agreements

Blackstone Life Sciences (“ BXLS”)

In March 2025, Takeda entered into a development funding agreement with BXLS for mezagitamab (TAK-079). Under this agreement, Takeda will receive up to a total of USD 300 240 300

14. Investments Accounted for Using the Equity Method

Financial information for associates accounted for using the equity method is as follows:

                                                      JPY (millions)                                                                                
                                                      For the Year Ended March 31                                                                   
                                                      2023                                           2024                     2025                  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Net profit (loss) for the year                      ¥                                ( 8,630)      ¥             6,473      ¥           ( 3,986)  
  Other comprehensive income (loss)                   ( 892)                                         ( 1,793)                 ( 145)                
  Total comprehensive income (loss) for the year      ¥                                ( 9,522)      ¥             4,681      ¥           ( 4,131)  

The carrying amount of the investments in associates accounted for using the equity method is as follows:

                                                                            JPY (millions)                                    
                                                                            As of March 31                                    
                                                                            2024                            2025              
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Carrying amount of investments accounted for using the equity method      ¥                   89,831      ¥         10,802  

15. Other Financial Assets

                                                                                        JPY (millions)                            
                                                                                        As of March 31                            
                                                                                        2024                                      
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Derivative assets (Note 27)                                                           ¥                   120,223       84,369  
  Investment in convertible notes at fair value through P& L (Note 27)                                       13,459       10,424  
  Investment in debt instruments (Note 27)                                                                    1,113       91,348  
  Investment in equity instruments at fair value through OCI (Note 27)